Chen, Chien-Ju
Sgritta, Martina
Mays, Jacqunae
Zhou, Hongyi
Lucero, Rocco
Park, Jin
Wang, I-Ching
Park, Jun Hyoung
Kaipparettu, Benny Abraham
Stoica, Loredana
Jafar-Nejad, Paymaan
Rigo, Frank
Chin, Jeannie
Noebels, Jeffrey L.
Costa-Mattioli, Mauro http://orcid.org/0000-0002-9809-4732
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (096816)
U.S. Department of Defense (AR120254)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS085171, NS29709)
Article History
Received: 22 February 2019
Accepted: 10 September 2019
First Online: 21 October 2019
Competing interests
: P.J.-N. and F.R. are employed by Ionis Pharmaceutical, a company that develops ASO therapies. The authors declare no other competing interests.